With facilities in New York, NY and in Rockville, MD and having strong ties to Harvard Medical and UCSF, Autonomous Therapeutics Inc is structured around development of broad-spectrum resistance-proof antivirals. An alumni of the NYC JLabs. and having a straight to Phase II DARPA SBIR Award, the firm's interdisciplinary team of virologists, synthetic biologists & robotics engineers are working on first-in-class pan-genus, broad-spectrum antivirals from COVID-19 to influenza. The driving theme is to ensure that effective countermeasures are ready before the next pandemic emerges.